The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

A rival CEO's confrontational social media post underscored the high stakes in the race to develop and deploy cancer ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

The biotech has been the subject of heavy insider buying this month, including by CEO Sergio Traversa, who purchased roughly $395,000 worth of shares at $2.82 each on Sept. 11. That marked the CEO ...

All seven independent directors of DNA-testing company 23andMe resigned, following a protracted negotiation with CEO Anne ...

Investing in biotech stocks can be risky, particularly in the clinical stage, since their success often hinges on the results ...

The space inside a newly developed Navy Yard building triples the French biotechnology company's footprint in Philadelphia.

CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce ...

suggesting the potential multiple roles of CM24 in overcoming immune evasion,” stated Purple Biotech CEO Gil Efron. “Moreover, these data enable us to potentially design biomarker- guided ...